
Cell Mind is at the forefront of AI in Cell Therapy, utilizing advanced deep learning algorithms to enhance CAR-T therapy processes. The company focuses on prescreening patients and predicting outcomes, aiming to streamline workflows and reduce costs in cell therapy, making treatments more accessible. With a team of experts from diverse fields, Cell Mind is dedicated to improving patient care through innovative biotech solutions and precise biomarker discovery, positioning itself as a leader in the biotechnology sector.

Cell Mind is at the forefront of AI in Cell Therapy, utilizing advanced deep learning algorithms to enhance CAR-T therapy processes. The company focuses on prescreening patients and predicting outcomes, aiming to streamline workflows and reduce costs in cell therapy, making treatments more accessible. With a team of experts from diverse fields, Cell Mind is dedicated to improving patient care through innovative biotech solutions and precise biomarker discovery, positioning itself as a leader in the biotechnology sector.
What they do: AI-driven tools to improve CAR‑T and other cell therapies (prescreening, analysis, outcome prediction)
Founded: 2023
Stage / size: Early-stage, pre-seed; headcount 1–10
Headquarters / registration: United States (Delaware registration; Baltimore contact listed)
Improving efficiency, accessibility, and effectiveness of cell therapies (notably CAR‑T) via AI-based prescreening and predictive analytics.
2023
Biotechnology
Stage: Pre-Seed